NAMS - NASDAQ

NewAmsterdam Pharma Company N.V.

NAMS·NASDAQ

$32.11

+4.5%

HealthcareBiotechnology

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.75B

EPS-1.7500

P/E Ratio-19.69

Earnings Date08/05/2026

nams

Cash at End of Period

Last Annual Value

491.32M

3-Year CAGR

5-Year CAGR

119%

10-Year CAGR

48%

Adjust for Inflation

NewAmsterdam Pharma Company N.V. Competitors Analysis of Cash at End of Period

NAMS · NASDAQ

Company	Cash at End of Period	CAGR 3Y	CAGR 5Y	CAGR 10Y
NewAmsterdam Pharma Company N.V. NASDAQ:NAMS	491.32M	13.0%	52.2%	N/A
Immunovant, Inc. NASDAQ:IMVT	902.11M	33.8%	17.7%	N/A
Praxis Precision Medicines, Inc. NASDAQ:PRAX	357.75M	63.6%	20.7%	N/A
Viking Therapeutics, Inc. NASDAQ:VKTX	165.81M	44.0%	44.4%	49.0%
Arcellx, Inc. NASDAQ:ACLX	82.88M	-40.8%	21.7%	N/A
Akero Therapeutics, Inc. NASDAQ:AKRO	340.24M	13.3%	17.7%	N/A
CG Oncology, Inc. Common stock NASDAQ:CGON	32.49M	57.8%	-9.5%	N/A
Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX	102.34M	22.1%	-12.6%	23.7%
Kymera Therapeutics, Inc. NASDAQ:KYMR	362.81M	46.3%	46.3%	N/A
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	174.93M	96.8%	55.0%	25.0%
Soleno Therapeutics, Inc. NASDAQ:SLNO	70.11M	-25.5%	26.9%	38.4%

NewAmsterdam Pharma Company N.V. Fair Value Envelope

NAMS · NASDAQ

Our analysis suggests that NAMS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.11, this represents a potential HIDDEN relative to our calculated worth for NewAmsterdam Pharma Company N.V..

HIDDEN

Intrinsic Value

Current Price: $32.11

Related Guides

Blog Categories

Continue your NAMS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.